Analysts at maintain a "Buy" rating with a target of $1,225 per share, representing a 33% implied upside.
Benefiting from a global NAND flash shortage and rapidly accelerating demand for fast AI storage. Emerging Market Feature: The "Real Economy" Rotation top five stocks to buy
Retains a "Strong Buy" rating with an estimated 20% upside potential. Analysts at maintain a "Buy" rating with a
Benefit from the ongoing boom in GLP-1 weight-loss drugs like Mounjaro and Zepbound. : 225 per share